ME Therapeutics Holdings Inc.
Research ME Therapeutics Holdings Inc. (Q9T) on Bullrun: market cap EUR 26.44M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerQ9T
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 26.44M
- Financial periodQ2 2026
- RevenueCAD 0
- Net income-CAD 398.35K
- Free cash flow-CAD 303.46K
Valuation Snapshot
latest market cap is EUR 26.44M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 1.25M | -CAD 1.25M | n/a | n/a | CAD 1.19M | CAD 57.39K | CAD 1.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 26.44M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ME Therapeutics Holdings Inc.
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ME Therapeutics Holdings Inc.'s market cap?
ME Therapeutics Holdings Inc.'s market capitalization is EUR 26.44M.
What does ME Therapeutics Holdings Inc. do?
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc.